|
|
 |
|
Viewing report
|
|
|
|
Effective Licensing & Commercialisation of Drug Delivery Systems 2006
PharmaVentures, Oct 2006, Pages: 161
Dedicated to the drug delivery sector, this report offers a concise and focused means of assessing and benchmarking drug delivery deal making activity over the past 9 years. It details valuation methodologies and explores effective deal structuring to ensure maximum returns. It is a critical report for all those involved in deal making across both the pharmaceutical and biotechnology sectors. This edition provides an up-to-date perspective of the drug delivery sector. It includes over 1400 drug delivery deals, over 50 drug delivery contracts and the latest company information.
Drug delivery is one of the most important sectors in the pharmaceutical industry and an area in which effective deal making is essential for survival and growth. Many smaller companies specialising in drug delivery systems rely upon deals for revenues, and larger pharmaceutical companies need access to their expertise and innovative technologies for the development of new products.
Effective deal making is particularly important in the present economic climate. The general downturn in equity markets over recent years has significantly weakened public share offerings as a means of raising the money that is required for rapid growth of drug delivery companies. Indeed, the NASDAQ biotech index fell by 45% during 20021 and the market for IPOs all but evaporated. The index had recovered to 80% of its 2001 value at the end of 2003, and grown a further 7% in 2004. At the end of 2005, it had reached 87% of the 2001 value. Nevertheless, as can be seen by the increase in the number of deals recorded in PharmaVentures’ PharmaDeals® Agreement, companies have been increasingly reliant upon the development of strategic alliances for gaining access to the funds that are required for product development and corporate expansion.
Effective Licensing & Commercialisation of Drug Delivery Systems 2006 encompasses issues that are vitally important to successful deal making within the drug delivery sector. The report begins with an assessment of the current and evolving drug delivery market, drug delivery companies and the challenges that are facing the drug delivery sector. The key driving factors that underlie the drug delivery sector are considered, including improving the therapeutic index of drugs, improving patient benefit and compliance, increasing the length of patent protection and product life cycle management. The report also reviews the business strategies that are employed for the commercialisation of drug delivery systems and there is an in-depth analysis of drug delivery alliances and their financial terms.
Integral to this report is a searchable management tool, which includes over 2000 drug delivery deals that transpired from May 1996 to the end of December 2005. This comprehensive source of drug delivery deals enables the gathering of competitive deal information including financial information. In addition, the database assists in obtaining knowledge of company relationships and partnerships that are vital to most drug delivery companies’ strategic business objectives.
The report also examines the drug delivery deal making activity of the top 10 pharmaceutical companies by healthcare sales, and identifies the deals with which these companies have been engaged to help recognise potential partners amongst the largest healthcare companies. The valuation methodologies that can be used when formulating deal terms are also described, including principles and rationale, deal bench marking and financial spreadsheet modelling.
The report includes an account of the process by which drug delivery deals are typically established from the initial steps of identifying the corporate needs, business opportunities and potential partners, through to the establishment of feasibility studies and full commercial alliances. Additionally, examples of genuine drug delivery agreements are provided that cover a variety of deal types including feasibility studies, licensing, collaborative R&D, commercialisation and product supply.
The drug delivery sector represents a dynamic, rapidly evolving sector as companies continue to vie for positions that will maximise commercial returns. Both markets and technologies continue to drive the sector, and it will be interesting to witness its evolution over the ensuing years.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
